FDA Attempts To Carve Out Regulatory Policy For Cytogenetic Tests
This article was originally published in The Pink Sheet Daily
Executive Summary
Array-based cytogenetic tests detect DNA copy number changes that may be indicative of congenital anomalies or developmental disabilities, but rather than a specific biomarker they can survey all or part of the entire genome and the results are open to interpretation.
You may also be interested in...
Array-based cytogenetic tests
FDA will host a workshop on array-based cytogenetic tests June 30 to address challenges in performance evaluation, determining clinical significance, and results reporting and interpretation. Cytogenetic tests detect pathological genomic copy number changes in a patient's DNA to identify abnormalities. FDA says these complex, array-based tests challenge "the traditional method of FDA review." The meeting will take place in Bethesda, Md. Comments on questions posed in a June 8 Federal Register 1notice are due July 30
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.